Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01231646 · ClinicalTrials.gov registry record

Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?

A clinical trial of Epilepsy and Psychiatric or Mood Diseases or Conditions, sponsored by Northwell Health.

Completed
Registry status
38
Enrollment target
1
Study location

NCT01231646: Completed study of Epilepsy and Psychiatric or Mood Diseases or Conditions, sponsored by Northwell Health.

NCT01231646 is a study of Epilepsy and Psychiatric or Mood Diseases or Conditions that has completed, run by Northwell Health. The registered enrollment target is 38 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01231646, a study of Epilepsy and Psychiatric or Mood Diseases or Conditions, has completed, sponsored by Northwell Health.

COMPLETED
Registry status
38 participants
Enrollment target
1
Study location

Study Summary

Women who take folate (folic acid) before getting pregnant can lower the risk of giving birth to infant with certain birth defects. However, some medications may affect the action of folate. The purpose of this study is to compare the effect of two anti-epileptic drugs on how folate works in our body.

Primary Outcome

ELISA assays using immobilized folate receptor protein were performed to determine the titers of immunoglobulin G, immunoglobulin M, and combined immunoglobulin G and immunoglobulin M to folate receptor in serum samples collected from both groups of women.

Interventions

  • OTHER No intervention

Study Locations (1)

New York

  • North Shore Long Island Jewish Health System - Great Neck

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2010-10
Est. Completion 2015-07
Northwell Health

370 total trials

What the finished NCT01231646 record still lists

NCT01231646 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.

NCT01231646 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01231646 about?

NCT01231646 is a clinical study titled "Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?". Women who take folate (folic acid) before getting pregnant can lower the risk of giving birth to infant with certain birth defects. However, some medications may affect the action of folate. The purpose of this study is to compare the effect of two anti-epileptic drugs on how folate works in our bod...

What is the current status of trial NCT01231646?

This trial is currently completed. The enrollment target is 38 participants. The study started on 2010-10. Estimated completion is 2015-07.

What conditions does trial NCT01231646 study?

This clinical trial studies the following conditions: Epilepsy, Psychiatric or Mood Diseases or Conditions.

What interventions are being tested in trial NCT01231646?

The interventions under investigation include: No intervention (OTHER).

Who is sponsoring clinical trial NCT01231646?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01231646 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01231646's enrollment target sits among peer trials

38 103rd of 160 higher than 57 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01231646, the US trial registry maintained by the National Library of Medicine. NCT01231646 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.